Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Rubius Therapeutics, Inc.

Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	2.45M -	22.04M 799.88%	39.89M 81.02%	57.18M 43.33%	50.34M 11.96%	53.03M 5.34%	30.84M 41.85%
selling general and administrative expenses	2.45M -	22.04M 799.88%	39.89M 81.02%	57.18M 43.33%	50.34M 11.96%	53.03M 5.34%	30.84M 41.85%
research and development expenses	8.40M -	21.23M 152.60%	51.77M 143.89%	112.42M 117.16%	116.11M 3.28%	141.59M 21.95%	96.41M 31.90%
other expenses	-16K -	-785K 4,806.25%	2.47M 414.39%	6.14M 148.91%	-1.28M 120.89%	-1.93M 50.51%	1.82M 194.46%
cost and expenses	10.85M -	43.26M 298.67%	91.66M 111.87%	169.60M 85.03%	166.45M 1.86%	194.62M 16.92%	127.25M 34.62%
operating expenses	10.85M -	43.26M 298.67%	91.66M 111.87%	169.60M 85.03%	166.45M 1.86%	194.62M 16.92%	127.25M 34.62%
interest expense	149K -	309K 107.38%	464K 50.16%	2.59M 458.19%	4.18M 61.58%	6.43M 53.74%	3.86M 39.96%
ebitda	-10.75M -	-42.31M 293.54%	-91.66M 116.67%	-169.60M 85.03%	-166.45M 1.86%	-194.62M 16.92%	-118.35M 39.19%
operating income	-10.85M -	-43.26M 298.67%	-91.66M 111.87%	-169.60M 85.03%	-166.45M 1.86%	-194.62M 16.92%	-178.45M 8.31%
depreciation and amortization	118K -	447K 278.81%	1.26M 182.55%	3.00M 137.13%	5.69M 90.02%	7.72M 35.71%	60.09M 678.12%
total other income expenses net	-15K -	-785K 5,133.33%	2.47M 414.39%	6.14M 148.91%	-1.28M 120.89%	-1.93M 50.51%	-1.22M 36.82%
income before tax	-11.02M -	-43.85M 298.03%	-89.19M 103.42%	-163.46M 83.26%	-167.73M 2.61%	-196.55M 17.18%	-179.67M 8.59%
income tax expense	133K -	309K 132.33%	2.93M 848.87%	-3.00M 202.15%	-5.69M 90.02%	-7.72M 35.71%	51.20M 762.92%
net income	-11.02M -	-43.85M 298.03%	-89.19M 103.42%	-160.46M 79.90%	-162.04M 0.98%	-188.82M 16.53%	-230.86M 22.26%
weighted average shs out	8.54M -	8.54M 0%	39.29M 359.89%	78.69M 100.30%	80.62M 2.46%	87.95M 9.09%	90.31M 2.68%
weighted average shs out dil	8.54M -	8.54M 0%	39.29M 359.89%	78.69M 100.30%	80.62M 2.46%	87.95M 9.09%	90.31M 2.68%
eps	-1.29 -	-5.13 297.67%	-2.27 55.75%	-2.04 10.13%	-2.01 1.47%	-2.15 6.97%	-2.56 19.07%
epsdiluted	-1.29 -	-5.13 297.67%	-2.27 55.75%	-2.04 10.13%	-2.01 1.47%	-2.15 6.97%	-2.56 19.07%

COM:RUBIUSTX

Rubius Therapeutics

Market Cap

5.16M

Beta: -

Preview